Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 20, 2020 - Issue 8
Submit an article Journal homepage
2,760
Views
12
CrossRef citations to date
0
Altmetric
Letter to the Editor

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

Marco Galluzzoa Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy;b Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3424-5175View further author information
ORCID Icon,
Lorenzo Tofania Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy;c Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyORCID Iconhttps://orcid.org/0000-0003-1286-9507View further author information
ORCID Icon,
Luca Bianchia Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy;c Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyView further author information
&
Marina Talamontia Dermatology Unit, Fondazione Policlinico Tor Vergata, Rome, Italy;c Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-3070-4071View further author information
ORCID Icon
Pages 829-830 | Received 28 May 2020, Accepted 03 Jun 2020, Published online: 16 Jun 2020

References

  • World Health Organization. [cited 2020 May 26]. Available from: https://covid19.who.int.
  • Gisondi P, Piaserico S, Conti A, et al. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020. DOI:10.1111/jdv.16515
  • Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180–190.
  • Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217–1218.
  • Brownstone ND, Thibodeaux QG, Reddy VD, et al. Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times. Dermatol Ther (Heidelb). 2020;10(3):1–11.
  • Galluzzo M, D’Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173–182.
  • SIDeMaST. [cited 2020 May 21]. Available from: https://www.sidemast.org/blog/proroga-dei-piani-terapeutici/
  • Di Lernia V, Bombonato C, Motolese A. COVID-19 in an elderly patient treated with secukinumab. Dermatol Ther. 2020:e13580. DOI: 10.1111/dth.13580. Epub ahead of print.
  • Megna M, Napolitano M, Fabbrocini G. May IL-17 have a role in COVID-19 infection? Med Hypotheses. 2020;140:109749.
  • Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 Pandemic. Am J Clin Dermatol. 2020. DOI:10.1007/s40257-020-00514-2.
  • Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345–346.
  • Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-e331.
  • Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020. DOI:10.1016/j.medmal.2020.05.001.
  • Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–10975.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.